Nektar Therapeutics $NKTR Shares Bought by US Bancorp DE

US Bancorp DE lifted its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 257.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,085 shares of the biopharmaceutical company’s stock after buying an additional 36,085 shares during the quarter. US Bancorp DE’s holdings in Nektar Therapeutics were worth $34,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nantahala Capital Management LLC boosted its holdings in Nektar Therapeutics by 90.0% in the fourth quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock worth $7,263,000 after purchasing an additional 3,700,000 shares during the period. Woodline Partners LP boosted its holdings in shares of Nektar Therapeutics by 187.3% in the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock valued at $4,626,000 after buying an additional 3,242,841 shares during the period. 22NW LP bought a new stake in shares of Nektar Therapeutics during the 4th quarter valued at about $2,038,000. Mackenzie Financial Corp grew its position in shares of Nektar Therapeutics by 253.1% during the 1st quarter. Mackenzie Financial Corp now owns 1,658,745 shares of the biopharmaceutical company’s stock valued at $1,128,000 after buying an additional 1,188,976 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Nektar Therapeutics by 17.5% during the fourth quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company’s stock worth $3,637,000 after acquiring an additional 583,153 shares during the period. Institutional investors own 75.88% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on NKTR. BTIG Research boosted their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, June 24th. Wall Street Zen cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 14th. B. Riley boosted their price objective on Nektar Therapeutics from $60.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a report on Monday, May 12th. Finally, HC Wainwright lifted their target price on Nektar Therapeutics to $120.00 and gave the company a “buy” rating in a research note on Tuesday, June 24th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $88.33.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR opened at $26.95 on Thursday. Nektar Therapeutics has a 1 year low of $6.45 and a 1 year high of $37.38. The firm has a market cap of $512.59 million, a P/E ratio of -3.06 and a beta of 0.95. The stock has a fifty day moving average price of $22.11 and a two-hundred day moving average price of $14.85.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($2.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.13) by $0.18. The company had revenue of $11.18 million for the quarter, compared to analysts’ expectations of $9.42 million. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%. On average, research analysts predict that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.